Quantitative analysis of the flavonoid glycosides and terpene trilactones in the extract of ginkgo biloba and evaluation of their inhibitory activity towards fibril formation of β-amyloid peptide

Molecules

Volumn 19, Issue 4, 2014, Pages 4466-4478

  Xie, Haiyan ^a   Wang, Jing Rong ^a,b   Yau, Lee Fong ^a,b   Liu, Yong ^a   Liu, Liang ^a,b   Han, Quan Bin ^a   Zhao, Zhongzhen ^a   Jiang, Zhi Hong ^a,b  

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^b China Macau University of Science and Technology Zhuhai MUST Science and Technology Research Institute   (Macao)

Author keywords

Flavonoid glycoside; Ginkgo biloba; Inhibitory activity; Quantitative analysis; Terpene trilactone; amyloid fibril formation

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); FLAVONOID; GINKGO BILOBA EXTRACT 761; GLYCOSIDE; LACTONE; PEPTIDE FRAGMENT; PLANT EXTRACT; TERPENE; THIAZOLE DERIVATIVE; THIOFLAVINE; TRILACTONE;

ANTAGONISTS AND INHIBITORS; CHEMISTRY; GINKGO BILOBA; HUMAN; ISOLATION AND PURIFICATION; PLANT LEAF; SPECTROFLUOROMETRY; STRUCTURE ACTIVITY RELATION;

AMYLOID BETA-PEPTIDES; FLAVONOIDS; GINKGO BILOBA; GLYCOSIDES; HUMANS; LACTONES; PEPTIDE FRAGMENTS; PLANT EXTRACTS; PLANT LEAVES; SPECTROMETRY, FLUORESCENCE; STRUCTURE-ACTIVITY RELATIONSHIP; TERPENES; THIAZOLES;

EID: 84899502690     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules19044466     Document Type: Article

References (19)

1. Cavallucci, V.; D'Amelio, M.; Cecconi, F. Aβ Toxicity in Alzheimer's Disease. Mol. Neurobiol. 2012, 45, 366-378.
2. Savonenko, A.V.; Melnikova, T.; Hiatt, A.; Li, T.; Worley, P.; Troncoso, J.C.; Wong, P.C.; Price, D.L. Alzheimer's Therapeutics: Translation of Preclinical Science to Clinical Drug Development. Neuropsychopharmacogy 2012, 37, 261-277.
3. Cott, J.M.; Raman, A. Clinical Efficacy and Pharmacodynamics. In American herbal Pharmacopoeia and Therapeutic Compendium: Ginkgo Leaf, Ginkgo Leaf Dry Extract, Ginkgo biloba L.; Herabalist, R.U., Graff, A., Eds.; American Herbal pharmacopoeia: Scotts Valley, CA, USA, 2003; pp. 26-27.
4. Levine, H., III. Thioflavine T interaction with synthetic Alzheimer's disease β-amyloid pepetides: Detection of amyloid aggregation in solution. Prot. Sci. 1993, 2, 404-410.
5. Nasr, C.; Lobstein-Guth, A.; Haag-Berrurier R.A. Quercetin coumaroyl glucorhamnoside from Ginkgo biloba. Phytochemistry 1987, 26, 2869-2870.
6. Nasr, C.; Haag-Berrurier R.A.; Lobstein-Guth, A.; Anton, R. Kaempferol coumaroyl glucorhamnoside from Ginkgo biloba. Phytochemistry 1986, 25, 770-771.
7. Tang, Y.P.; Wang, Y.; Lou, F.C.; Li, Y.F.; Wang, J.H. Flavonol glycosides from the leaves of Ginkgo biloba. Acta Pharm. Sin. 2000, 35, 363-366.
8. Gao, J.H.; Shi, F.G.; Song, G.Q. Further NMR investigation and conformational analysis of an acylated flavonol glucorhamanoside. Magn. Reson. Chem. 1996, 34, 249-254.
9. The United States Pharmacopeial Convention. The United States Pharmacopeia, 28th Revision/National Formulary, 23rd ed.; The United State Pharmacopeial Convention: Rochville, MD, USA, 2003; pp. 2094-2095.
10. Ono, K.; Yoshiike, Y.; Takashima, A.; Hasegawa, K.; Naiki, H.; Yamada, M. Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease. J. Neurochem. 2003, 87, 172-181.
11. Ramassamy, C.; Christen, Y.; Poirier, J. Ginkgo biloba extract (EGb761), β-amyloid peptide and apolipoprotein E in Alzheimer's disease. In Advances in Ginkgo biloba Extract (EGb761) as a Neuroprotective Agent: From Basic Studies to Clinical Trial; Christen, Y., Ed.; Solal: Marseille, France, 2001; Volume 8, pp. 71-89.
12. Luo, Y.; Smith, J.V.; Paramasivam, V.; Burdick A.; Curry, K.J.; Buford J.P.; Khan, I.; Netzer W.J.; Xu, H.X.; Butko P. Inhibition of amyloid-β aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc. Natl. Acad. Sci. USA 2002, 99, 12197-12202.
13. Jiang, Z.-H.; Tanaka, T.; Kouno, I. Chilianthins A-F, six triterpene esters having dimeric structures from Rhoitelea chiliantha DIELS et HAND.-MAZZ. Chem. Pharm. Bull. 1996, 44, 1669-1675.
14. Jao, S.C.; Ma, K.; Talafous, J.; Orlando, R.; Zagorski, M.G. Trifluoroacetic acid pretreatment reproducibly disaggregates the amyloid β-peptide. Amyloid Int. J. Exp. Clin. Invest. 1997, 4, 240-252.
15. Naiki, H.; Hasegawa, K.; Yamaguchi, I.; Nakamura, H.; Gejyo, F.; Nakakuki, K. Apolipoprotein E and antioxidants have different mechanisms of inhibiting Alzheimer's beta-amyloid fibril in vitro. Biochemistry 1998, 37, 17882-17889.
16. Ono, K.; Hasegawa, K.; Yamada, K.; Naiki, H. Nicotine breaks down performed Alzheimer's beta-amyloid fibril in vitro. Biol. Psychiatry. 2002, 52, 880-886.
17. Porat, Y.; Abramowitz, A.; Gazit, E. Inhibition of amyloid fibril formation by polyphenols: Structural similarity and aromatic interactions as a common inhibition mechanism. Chem. Biol. Drug. Des. 2006, 67, 27-37.
18. Zhang, H.Y.; Wang, J.R.; Yau, L.F.; Ho, H.M.; Chan, C.L.; Hu, P.; Liu, L.; Jiang, Z.H. A cellular lipidomic study on the Aβ-induced neurotoxicity and neuroprotective effects of EGCG by using UPLC/MS-based glycerolipids profiling and multivariate analysis. Mol. Biosyst. 2012, 8, 3208-3215.
19. Bai, L.P.; Ho, H.M.; Ma, D.L.; Yang, H.; Fu, W.C.; Jiang, Z.H. Aminoglycosylation can enhance the G-quadruplex binding activity of epigallocatechin. PLoS One 2013, 8, e53962.